June 22 - 26, 2018
Boston Marriott Copley Place
Boston, Massachusetts, USA
Abstract submission deadline: Friday, April 6
Advance registration deadline: Friday, May 11
Abstract Submission Deadline: Friday, April 6, 2018, 11:59 p.m. ET
Guidelines for Preparation and Submission of Abstracts
AACR Abstract Submission System. Authors must submit abstracts for presentation at the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application using the
AACR Online Abstract Submission System. You can create, modify, and submit abstracts until the
Friday, April 6, submission deadline.
Content of Abstracts. Authors who submit abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application.
Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.
Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition (Council of Science Editors, 2014).
Copyright Transfer/Abstract Presentation. On behalf of all authors, the corresponding author must:
Abstract Control Number. An abstract control number (e.g., 17-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.
Financial Relationships of Co-Authors. Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of all of your co-authors. For more information on financial relationships, visit the Continuing Medical Education webpage.
Length of Abstracts. The combined length of the abstract body, title, and tables may not exceed
2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.
Disclosure of Chemical Structures. At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required. The Scientific Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts may be accepted for presentation if deemed to be of sufficient scientific merit.
Submission Deadline. The deadline for abstract submissions is
11:59 p.m. US EST on Sunday, April 8, 2018. Abstracts submitted in any form after the deadline will not be considered by the Scientific Committee.
Top of page
Deadline for Withdrawal of Abstracts. The AACR cannot comply with any request for withdrawal of an abstract that will delay the publication of the
Program. However, requests to withdraw abstracts will be accepted through
Friday, May 25, 2018. Withdrawal requests must be sent by email to
firstname.lastname@example.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.
Opportunities for Short Talks from Abstracts. The Scientific Committee will evaluate highly rated abstracts and where thematically appropriate, invite authors to present a short talk during the program. All accepted abstracts are eligible. Not all sessions will include short talks.
Best Poster Prizes. All abstracts accepted for poster presentation at the meeting will be eligible for one of three “Best Poster Prizes” selected by a subcommittee comprised of members of the Scientific Committee. Posters will be judged based on their scientific merit, relevance, clarity, and overall presentation. Awardees will be provided with complimentary registration to the Second AACR International Meeting Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application to be held in June 2020.
Release Date for Abstracts. All accepted abstracts are scheduled to be posted online via the conference itinerary planner and app on
Friday, June 8, 2018. Abstracts will not be available before this date.
Presentation of Abstracts. Every abstract that has been accepted for publication in the online
Proceedings must also be presented at the meeting. Specifically, the author listed as the presenter must register for the meeting and attend the session in which the abstract is scheduled to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the abstract, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no authors are available to present the abstract, the presenter must withdraw the abstract by submitting a withdrawal request by email to
email@example.com. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal..
Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:
Top of page
Clinical Trials and Placeholder Abstract DeadlineAll abstracts describing clinical trials, including trials in progress, should be submitted by the
Friday, April 6 deadline using the Therapeutics and Clinical Trials in Lymphoma category or the Placeholder: Clinical Trials in Lymphoma category. Except for Trials in Progress, abstracts may be submtted under the Placeholder: Clinical Trials in Lymphoma category with the objectives of the study, methodology, and preliminary data or an indication of the type of results anticipated. The full abstract, including final results and conclusions, is due
Friday, May 4, 2018.